Atrion Corporation (ATRI) Bundle
A Brief History of Atrion Corporation (ATRI)
Founding and Early Years
Atrion Corporation was founded in 1980 by Dr. Emile F. DeBakey and other co-founders. The company began operations focused on developing medical devices and specialized products for the healthcare sector.
Public Offering and Growth
In 1992, Atrion Corporation went public, with an initial public offering (IPO) price of $1.00 per share. The company has seen steady growth since then. By 2022, Atrion reported total revenue of approximately $92.9 million.
Product Development and Innovations
Atrion has continuously expanded its product portfolio. Some key products include:
- Flow Control Devices
- Cardiovascular Products
- Dialysis Products
- Wound Care Products
Financial Performance
In 2023, Atrion reported a net income of $16.8 million. The company’s earnings per share (EPS) for the same year was approximately $3.85.
Market Capitalization
As of October 2023, Atrion Corporation's market capitalization was around $530 million.
Dividend Policy
Atrion has a consistent dividend payout history. In the year 2023, the company declared a cash dividend of $1.00 per share, resulting in a dividend yield of approximately 1.8%.
Employee Base
As of 2023, Atrion Corporation employed around 250 individuals, all contributing to various segments of product development, sales, and administration.
Recent Developments
In 2023, the company announced plans to invest $10 million in expanding its manufacturing capabilities to meet rising demand in international markets.
| Year | Total Revenue ($ Million) | Net Income ($ Million) | EPS ($) | Market Cap ($ Million) | Dividends per Share ($) |
|---|---|---|---|---|---|
| 2020 | 85.0 | 13.2 | 3.02 | 450 | 0.85 |
| 2021 | 89.5 | 15.0 | 3.42 | 480 | 0.90 |
| 2022 | 92.9 | 16.0 | 3.78 | 500 | 0.95 |
| 2023 | 95.0 | 16.8 | 3.85 | 530 | 1.00 |
Corporate Social Responsibility
Atrion Corporation has been involved in various community initiatives, including health education and local charity support, enhancing its reputation as a socially responsible organization.
Future Outlook
The company is focused on expanding its research and development efforts, anticipating an increase in revenue by 10% over the next five years. Atrion aims to penetrate new markets, particularly in Europe and Asia.
Conclusion and Strategic Directions
Atrion Corporation continues to evolve within the medical device industry, maintaining a strong financial position and advancing its product offerings.
A Who Owns Atrion Corporation (ATRI)
Shareholder Structure
Shareholder Structure
Atrion Corporation (ATRI) has a diverse shareholder base that includes institutional investors, individual shareholders, and company insiders. As of the latest reporting date, the ownership distribution is as follows:
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 55.3% | 1,222,900 |
| Insiders | 10.8% | 237,300 |
| Retail Investors | 33.9% | 738,700 |
Top Institutional Shareholders
Institutional investors play a significant role in supporting Atrion Corporation’s stock. The top institutional shareholders are as follows:
| Institution | Percentage Ownership | Number of Shares |
|---|---|---|
| The Vanguard Group, Inc. | 9.5% | 210,000 |
| BlackRock, Inc. | 6.8% | 150,000 |
| American Century Investments | 5.2% | 115,000 |
| Wellington Management Co. LLP | 4.1% | 90,000 |
| Southeast Asset Advisors, Inc. | 3.7% | 80,000 |
Insider Ownership
Insider ownership is a critical factor in understanding the governance of Atrion Corporation. The following are notable insiders and their respective shareholdings:
| Name | Position | Shares Owned |
|---|---|---|
| Dr. Emory W. K. L. Tsao | Chairman | 125,000 |
| Mr. Timothy W. H. Tsao | CEO | 100,000 |
| Ms. Angela H. D. Wu | CFO | 12,000 |
| Mr. Steven H. Ko | COO | 10,000 |
Recent Stock Performance
The stock performance of Atrion Corporation can provide insights into the market perception of the company:
- Current Share Price: $272.80
- 52-Week High: $290.00
- 52-Week Low: $220.00
- Market Capitalization: $675 million
Key Financial Metrics
Atrion Corporation has demonstrated solid financial health, reflected in the following key metrics:
| Metric | Value |
|---|---|
| Revenue (Last Fiscal Year) | $146 million |
| Net Income | $32 million |
| Earnings Per Share (EPS) | $9.00 |
| Debt-to-Equity Ratio | 0.05 |
| Return on Equity (ROE) | 15.5% |
Investor Relations
Atrion Corporation maintains an active investor relations program that provides shareholders with essential information:
- Annual Reports: Available on the company's website
- Quarterly Earnings Calls: Held after the release of quarterly results
- Investor Presentations: Updated regularly to reflect the company's strategic initiatives
Atrion Corporation (ATRI) Mission Statement
Company Overview
Company Overview
Atrion Corporation, listed on the NASDAQ as ATRI, focuses on the development and commercialization of medical devices and products for various healthcare applications. Founded in 1981, the company has evolved to serve a wide range of markets, including cardiovascular, ophthalmology, and urology.
Mission Statement
Atrion Corporation’s mission is to enhance patient outcomes through the development of innovative medical technologies. The company emphasizes quality, reliability, and integrity in all its operations, aiming to improve healthcare systems while delivering value to its stakeholders.
Core Values
-
Innovation: Commitment to advancing medical science and technology.
-
Quality: Unwavering dedication to product quality and safety.
-
Integrity: Operating with honesty and transparency in all dealings.
-
Customer Focus: Prioritizing the needs and satisfaction of patients and healthcare providers.
Financial Performance
- Innovation: Commitment to advancing medical science and technology.
- Quality: Unwavering dedication to product quality and safety.
- Integrity: Operating with honesty and transparency in all dealings.
- Customer Focus: Prioritizing the needs and satisfaction of patients and healthcare providers.
Financial Performance
As of the end of 2022, Atrion Corporation reported the following financial metrics:
| Financial Metric | 2022 Amount (in Millions) | 2021 Amount (in Millions) |
|---|---|---|
| Revenue | $77.2 | $74.9 |
| Net Income | $20.3 | $18.5 |
| Operating Income | $23.4 | $21.8 |
| Total Assets | $155.7 | $147.6 |
| Total Liabilities | $33.9 | $29.5 |
Market Presence
Atrion's products are utilized across various healthcare sectors, contributing to the company's robust market presence. The company maintains a global footprint, with its products available in over 60 countries. The key segments include:
- Cardiovascular Devices
- Ophthalmic Products
- Urological Devices
- Critical Care Products
Commitment to R&D
Atrion Corporation invests significantly in research and development, with an approximate annual expenditure of $7.7 million as of 2022. This investment underlines the company’s commitment to innovation and the development of new medical technologies.
Regulatory Compliance
Atrion’s products adhere to stringent regulatory standards, including the following certifications:
- FDA Approval for various medical devices
- ISO 13485 certification for quality management systems
- CE Marking for compliance within the European market
Community Engagement
Atrion Corporation engages with local communities through various initiatives, responding to healthcare needs and supporting local health programs. The company also participates in educational outreach and promotes health awareness campaigns.
Future Outlook
Looking ahead, Atrion aims to expand its product portfolio and improve its manufacturing capabilities while continuing to prioritize quality and innovation. The projected revenue growth for 2023 is estimated at approximately 5% to 7% based on market trends and existing product performance.
How Atrion Corporation (ATRI) Works
Company Overview
Atrion Corporation specializes in the development and manufacturing of medical devices and systems. As of the latest financial reports, Atrion operates in several key segments including cardiovascular products, surgical products, and urinary drainage systems.
Financial Performance
For the fiscal year ending December 31, 2022, Atrion reported:
- Revenue: $97.4 million
- Gross Profit: $67.8 million
- Net Income: $19.5 million
- Earnings Per Share (EPS): $3.45
| Year | Revenue (in millions) | Net Income (in millions) | EPS |
|---|---|---|---|
| 2020 | $80.2 | $17.2 | $3.06 |
| 2021 | $85.6 | $18.3 | $3.25 |
| 2022 | $97.4 | $19.5 | $3.45 |
Market Position
Atrion holds a significant position within the medical device industry. As of 2022, it commands approximately 0.5% of the total market share in the cardiac device market. The global market size for medical devices is projected to reach approximately $600 billion by 2025.
Research and Development (R&D)
Atrion invests heavily in R&D, with an estimated 10% of revenue allocated towards enhancing existing products and developing new technologies. In 2022, the R&D expenditure amounted to approximately $9.7 million.
Product Lines
Atrion's main product lines include:
- Cardiovascular Products: Catheters and related accessories
- Surgical Products: Surgical sutures and other surgical devices
- Urinary Drainage Systems: Intermittent catheters and other urological products
Distribution Channels
The company's products are distributed through various channels, including:
- Direct Sales Force: Engaged in promoting and selling products directly to healthcare providers
- Distributors: Partnerships with distributors for wider reach
- E-commerce: Online platforms for direct consumer sales
Stock Performance
As of October 2023, Atrion Corporation's stock (NASDAQ: ATRI) has shown:
- Current Stock Price: $210.45
- Market Capitalization: Approximately $1.1 billion
- 52-Week Range: $180 - $230
Competitive Landscape
Atrion faces competition from major players in the medical device industry, including:
- Medtronic
- Boston Scientific
- Stryker Corporation
Future Outlook
Analysts forecast that Atrion's revenue growth could reach 5% annually over the next five years, driven by advancements in medical technology and increasing demand for high-quality medical devices.
How Atrion Corporation (ATRI) Makes Money
Business Segments
Atrion Corporation operates primarily through three business segments: Fluid Delivery Systems, Medical Devices, and Other Products.
Fluid Delivery Systems
This segment encompasses products used for intravenous therapy, including IV sets and related products. In 2022, revenue from fluid delivery systems accounted for approximately $32 million.
Medical Devices
The medical devices segment includes advanced wound care products, vascular access products, and other specialized medical devices. In 2022, the revenue from medical devices was around $28 million.
Other Products
This category includes various other products that do not fall under the primary segments. Revenue from other products totaled about $5 million in 2022.
Revenue Breakdown by Segment
| Segment | 2022 Revenue (in millions) | Percentage of Total Revenue |
|---|---|---|
| Fluid Delivery Systems | $32 | 53% |
| Medical Devices | $28 | 46% |
| Other Products | $5 | 1% |
Market Strategy
Atrion focuses on innovation and product development to sustain its competitive edge. The company allocates approximately 10% of its annual revenue towards research and development.
Key Financials
For the fiscal year ending December 31, 2022, Atrion Corporation reported total revenues of $65 million. The company’s net income for the same period was approximately $12 million, resulting in a net profit margin of around 18.5%.
Recent Performance Indicators
| Year | Total Revenue (in millions) | Net Income (in millions) | Net Profit Margin |
|---|---|---|---|
| 2020 | $58 | $9 | 15.5% |
| 2021 | $61 | $10.5 | 17.2% |
| 2022 | $65 | $12 | 18.5% |
Geographic Distribution
Atrion's market presence is primarily in the United States, but it also has growing international sales. In 2022, international sales contributed to approximately 20% of total revenues.
Future Outlook
- Atrion aims to expand its product line in vascular access and wound care markets to drive growth.
- The company plans to enhance its distribution network to capture more international market share.
- Investment in technological advancements to maintain product quality and improve manufacturing efficiency is a priority.
Atrion Corporation (ATRI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support